SGMO - Sangamo Therapeutics

-

$undefined

N/A

(N/A)

Sangamo Therapeutics NasdaqCM:SGMO Sangamo Therapeutics, Inc., a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; and SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A. Its preclinical development products focus on tauopathies, ALS/FTD, and huntington's diseases Sangamo Therapeutics, Inc. has collaborative and strategic partnerships with Biogen MA, Inc.; Kite Pharma, Inc.; Pfizer Inc.; Sanofi S.A.; Novartis Institutes for BioMedical Research, Inc.; Shire International GmbH; Dow AgroSciences LLC; Sigma-Aldrich Corporation; Genentech, Inc.; and Open Monoclonal Technology, Inc. The company was formerly known as Sangamo BioSciences, Inc. and changed its name to Sangamo Therapeutics, Inc. in January 2017. The company was incorporated in 1995 and is headquartered in Richmond, California.

Location: 501 Canal Blvd, Richmond, CA, 94804, United States | Website: https://www.sangamo.com | Industry: Biotechnology | Sector: Healthcare


Market Cap

NaN

52 Wk Range

$ - $

Previous Close

$N/A

Open

$N/A

Day Range

N/A - N/A

Volume

N/A

Avg Volume

N/A

Enterprise Value

106.4M

Cash

25.18M

Avg Qtr Burn

-11.16M

Short % of Float

14.05%

Insider Ownership

2.80%

Institutional Own.

22.35%

Qtr Updated

03/31/25


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & IndicationStage & EventCatalyst Date
Giroctocogene fitelparvovec (SB-525 / PF-07055480) Details
Rare diseases, Hemophilia, Rare genetic disease, Blood disorder

Phase 3

Update

Phase 1/2

Data readout

TX-200 Details
Kidney disease, Kidney transplantation

Phase 1/2

Update

ST-503 Details
Idiopathic small fiber neuropathy

Phase 1/2

Initiation

ST-506 Details
Prion disease

IND

Submission

ST-400 Details
Blood disorder, Beta thalessemia

Failed

Discontinued

SB-913 Details
Genetic disorder, Rare diseases, Mucopolysaccharidoses, Rare genetic disease, Mucopolysaccharidosis type II

Failed

Discontinued

BIVV003 (SAR445136) Details
Sickle cell disease, Blood disorder

Failed

Discontinued